Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

Presentation TCT 2019

PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Vinod Thourani

September 28, 2019

Presentation TCT 2017

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

Presenter: Steven R. Bailey, Patrick W. Serruys, Angelo Biviano, MD

November 01, 2017

Presentation TCT 2017

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Presenter: Patrick W. Serruys, David J. Cohen

October 31, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2014

Updates from PARTNER 2A and Sapien 3 in Intermediate-Risk Patients

Presenter: Martin B. Leon, Neil E. Moat, Ariel Finkelstein, Vinod H. Thourani

September 13, 2014

Presentation TCT 2013

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Presenter: Jodi Akin

October 30, 2013

Presentation TCT 2013

Status Update on the Randomized Moderate Risk AS Trials: PARTNER 2A

Presenter: Martin Leon

October 27, 2013

Presentation TCT 2012

Update from the Randomized PARTNER 2A Trial

Presenter: Martin Leon

October 22, 2012

Advertisement

PARTNER 2A: 5-Year Outcomes From a Randomized Trial of Transcatheter vs. Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

TCT 8391: Atrial Fibrillation Is Associated With Increased Mortality in Intermediate-Risk Patients Undergoing TAVR or SAVR - Insights From the PARTNER 2A and PARTNER 2 S3i Trials

PARTNER 2A and SAPIEN 3 Cost-effectiveness: Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Updates from PARTNER 2A and Sapien 3 in Intermediate-Risk Patients

Lessons Learned from PARTNER 2A and SURTAVI: Device Specificity, Trial Design, Endpoints, and Future Low-risk Studies

Status Update on the Randomized Moderate Risk AS Trials: PARTNER 2A

Update from the Randomized PARTNER 2A Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content